Form 4: ARDELYX CFO Boosts Stake with RSU and Option Grants

ARDELYX's Chief Financial Officer, Susan Hohenleitner, acquired 85,670 restricted stock units and 128,505 stock options on January 23, 2026.

Summary

• Susan Hohenleitner, Chief Financial Officer of ARDELYX, INC. (ARDX), acquired 85,670 shares of Common Stock in the form of Restricted Stock Units (RSUs) on January 23, 2026.
• Each RSU entitles the Reporting Person to receive one share of Common Stock upon vesting, with an acquisition price of $0.
• Following this transaction, the Reporting Person beneficially owns 232,566 shares of Common Stock directly.
• Additionally, Hohenleitner acquired 128,505 stock options (right to buy) with an exercise price of $7.77 per share on January 23, 2026.
• These stock options have an expiration date of January 23, 2036, and were acquired at a price of $0.
• The options vest in 48 successive, equal monthly installments starting from January 23, 2026, contingent on continued employment or service with ARDELYX.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The Chief Financial Officer's acquisition of a significant number of restricted stock units and stock options indicates a strong alignment of interests with shareholders and confidence in the company's future performance.

Positives

• The Chief Financial Officer's acquisition of 85,670 Restricted Stock Units and 128,505 stock options demonstrates increased alignment of management's interests with those of shareholders.
• The use of a Rule 10b5-1(c) plan for these transactions indicates a pre-arranged trading strategy, which can enhance transparency and mitigate concerns about opportunistic insider trading.

Risks

• The vesting of both the 85,670 Restricted Stock Units and the 128,505 stock options is contingent upon the Reporting Person's continued employment or service relationship with ARDELYX, posing a personal risk of forfeiture if employment ceases.

Future Outlook

The equity grants, particularly the stock options with a 10-year expiration and a 4-year vesting schedule, suggest a long-term commitment from the Chief Financial Officer to the company's future performance and growth, aligning personal incentives with sustained shareholder value creation.

Industry Context

Executive equity compensation, including RSUs and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key management personnel. These grants are designed to align the interests of executives with long-term shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of the Chief Financial Officer's financial interests with long-term shareholder value.
• Employees: Demonstrates management's commitment to the company, potentially boosting morale and confidence.

Next Steps

• The Restricted Stock Units will vest, entitling the Reporting Person to shares of Common Stock.
• The stock options will vest in 48 successive, equal monthly installments, allowing the Reporting Person to exercise them over time, subject to continued employment.

Key Dates

Keywords

ARDX, ARDELYX, Form 4, Insider Transaction, CFO, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Rule 10b5-1